NCT06456411

Brief Summary

This study aims to develop objective tools for assessing perceived pain severity in cancer patients and survivors, evaluate the sustained effectiveness of non-pharmacological interventions such as virtual reality in reducing pain and medication use, and create tools for the early detection of neuropathy. Wireless, non-invasive neuroimaging methods, including functional near-infrared spectroscopy (fNIRS), will be used to support these objectives

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
106

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 12, 2022

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

May 30, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 13, 2024

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 10, 2026

Completed
Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

3.7 years

First QC Date

May 30, 2024

Last Update Submit

April 23, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Gain knowledge of Brain activity during pain

    Computational neuroscience algorithms and graph theories will be used to extract informative patterns of brain activity and diagnose the stimulated brain areas associated with pain and pain severity as well as any relationships between pain severity, functional near-infrared spectroscopy (fNIRS) measures, and visual perception.

    Up to 16 months

Secondary Outcomes (2)

  • Determine if utilizing virtual reality technologies significantly alleviate pain through distraction

    Up to 16 months

  • Reason for pain alleviation caused by virtual reality techniques

    Up to 16 months

Study Arms (6)

Group A (fNIRS)

EXPERIMENTAL

Participants undergo fNIRS for 10 minutes.

Procedure: Functional Near-Infrared SpectroscopyOther: Questionnaire Administration

Group B (fNIRS, VR)

EXPERIMENTAL

Patients undergo fNIRS for 10 minutes followed by a relaxation period using VR for over 15 minutes.

Procedure: Functional Near-Infrared SpectroscopyOther: Questionnaire AdministrationOther: Virtual Technology Intervention

Group C (fNIRS)

EXPERIMENTAL

Patients undergo fNIRS for 10 minutes.

Procedure: Functional Near-Infrared SpectroscopyOther: Questionnaire Administration

Group D Arm 1 - VR

EXPERIMENTAL

Patients undergo Therapeutic VR program for up to 30 minutes four times per week

Other: Virtual Technology Intervention

Group D Arm II - Sham VR

EXPERIMENTAL

Patients undergo placebo VR program for up to 30 minutes four times per week.

Other: Virtual Technology Intervention

Group E

EXPERIMENTAL

Cold stimulation on day 1 of each chemotherapy cycle and day 3.

Other: Cold Stimulation

Interventions

Undergo fNIRS

Also known as: fNIRS, Functional Near Infrared Spectroscopy, Functional NIR Spectroscopy, Functional Optical Brain Imaging
Group A (fNIRS)Group B (fNIRS, VR)Group C (fNIRS)

Ancillary studies

Group A (fNIRS)Group B (fNIRS, VR)Group C (fNIRS)

Undergo relaxation period using VR

Also known as: Virtual Reality Intervention, Virtual Technology
Group B (fNIRS, VR)Group D Arm 1 - VRGroup D Arm II - Sham VR

cold stimulation using ice pack

Also known as: ice pack
Group E

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cancer pts as well as healthy volunteers) must be over the age of 18
  • Participants in Groups A or C (cancer pts as well as healthy volunteers) need to be able to be in a sedentary posture for approximately 20 minutes
  • Participants in Group B and C: Patient can be in any stage of cancer treatment, such as diagnosis, treatment (surgery, chemotherapy, immunotherapy, radiation), recovery, remission and is experiencing acute pain from treatment or cancer itself. Cancers include but are not limited to: breast, thoracic, lung, kidney, colon, pancreatic, etc.
  • Participants in Group B and C must be free from other forms of chronic pain, e.g., rheumatologic pain, must be free from neurologic illnesses, e.g., stroke, and must have no brain metastases which could interfere with brain functions
  • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
  • Men and women of 40-80 yrs old
  • Stage I-III lung cancer survivors who have undergone lung resection and developed persistent post-thoracotomy pain (PPTP)
  • Willing to comply with study procedures
  • Be able to remain sedentary for 20 minutes during functional near-infrared spectroscopy (fNIRS) data recording sessions, including 10 minutes each for fNIRS system setup and 10 minutes data recording.
  • Female participants must not be pregnant to participate in this study. During the third trimester, the fetus's brain is significantly developed and may interact with the mother's brain. As this study involves recording brain activity using fNIRS, it is necessary to exclude pregnant individuals to ensure the quality of the research data.
  • Be able to remove any items from their scalp that might block direct contact between the fNIRS optodes and the skin. This includes, but is not limited to, wigs and hijabs.
  • Must be free from other forms of chronic pain, e.g., rheumatologic pain
  • Must be free from neurologic illnesses, e.g., stroke
  • Had no brain metastases which could interfere with brain functions
  • Must understand the investigational nature of the study and sign a written informed consent form approved by the Independent Ethics Committee/Institutional Review Board.
  • +5 more criteria

You may not qualify if:

  • Unwilling or unable to follow protocol requirements
  • Currently pregnant or planning to become pregnant during the study period
  • FOR GROUP B :
  • Medical condition predisposing to nausea or dizziness.
  • Hypersensitivity to flashing light or motion.
  • stereoscopic vision or severe hearing impairment.
  • Unwillingness or inability to follow protocol requirements.
  • Individuals with impaired decision-making capacity.
  • Individuals with electronic or metallic implants in the head.
  • Unable to remove any items from their scalp that might block direct contact between the fNIRS optodes and the skin. This includes, but is not limited to, wigs and hijabs
  • Prisoners
  • individuals with hypersensitivity to flashing lights or motion. Rationale: Such hypersensitivities can increase the risk of seizures or severe discomfort when exposed to common elements of VR programs, which frequently include rapid visual and motion stimuli.
  • individuals with impaired stereoscopic vision or severe hearing impairments. Rationale: VR programs often involve moving objects, flashing lights, and immersive soundscapes. Participants must have sufficient vision and hearing to effectively engage with and safely navigate these environments.
  • Currently pregnant or planning to become pregnant during the study period.
  • Unwillingness or inability to follow protocol requirements.
  • +18 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

Location

MeSH Terms

Conditions

Breast NeoplasmsCarcinoma, Renal CellCarcinoma

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesAdenocarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Somayeh B Shafiei

    Roswell Park Cancer Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2024

First Posted

June 13, 2024

Study Start

July 12, 2022

Primary Completion

April 10, 2026

Study Completion

April 10, 2026

Last Updated

April 29, 2026

Record last verified: 2026-04

Locations